Coming Carcinogenicity Of Radiofrequency Microwaves Decision Rebuked - Without Full Disclosure Of Interphone Study Any Opinion 'Irresponsible'
In collaboration with the International EMF Alliance (IEMFA), scientists from Europe, North America, Australia and Israel have sent an Open Letter to Dr. Christopher Wild, Director of the International Agency for Research on Cancer (IARC), calling for a postponement of the forthcoming meeting May 24-31, 2011 in Lyon, France, "Non-Ionizing Radiation, Part II: Radiofrequency Electromagnetic Field [includes mobile telephones], " at which determination of the carcinogenicity of cell phones and wireless technologies will be made.
Eisai's Eribulin Halaven R Receives Swissmedic Approval For Use In Locally Advanced And Metastatic Breast Cancer
Eribulin (Halaven(R)) is today approved for use in Switzerland by Swissmedic, the Swiss Agency for Therapeutic Products, as a monotherapy treatment of patients with locally advanced and metastatic breast carcinoma with progression after prior therapy with an anthracycline, a taxane and capecitabine.[1] Breast cancer is the second most commonly diagnosed cancer worldwide and there are about 1.3 million new cases of the disease annually.[2] More than 5, 000 Swiss women have the disease and approximately 1, 400 are likely to die annually.
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Russia
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine® , the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia. The study is already ongoing at several clinical sites in the United States, Canada, Poland and India. The total study is expected to enroll about 880 head and neck cancer patients in about 48 hospitals in 9 countries on three continents.